Nicholas Clifton
Senior Research Fellow
Research Interests
Make your next move.
Prepare your application
Review drafts before you send them.
Explore related searches
Articles (12)
Objective Dystonia is one of the most common movement disorders, with variants in multiple genes identified as causative. However, an understanding of which developmental stages, brain regions, and cell types are most relevant is crucial for developing relevant disease models and therapeutics. One approach is to examine the timing and anatomical expression of genes in which variants are dystonia‐causing, on the assumption that deleterious variants have a greater impact where higher levels of expression are observed. Methods We investigated the expression patterns of 44 genes linked with a dystonia phenotype across two bulk and two single‐nuclei RNA‐sequencing datasets, derived from prenatal and postnatal human brain tissue. Results Dystonia genes were most strongly enriched in the striatum, cerebral cortex, hippocampus, amygdala and substantia nigra, and demonstrated higher postnatal expression. Individual genes exhibiting differences in expression across adult brain regions include SQSTM1 , SGCE , KMT2B , PRKRA , YY1 , DNAJC12 , KCNA1 , CACNA1A (highest expression in cerebellum), ADCY5 , GNAL , ANO3 (highest expression in striatum), RHOBTB2 , FOXG1 (highest expression in cerebral cortex). Single‐nuclei RNA‐sequencing analyses from human frontal cortex, striatum, cerebellum and substantia nigra indicated that dystonia genes are predominantly expressed in neurons (glutamatergic, GABAergic and dopaminergic). Gene Ontology analysis showed prominent enrichment in biological processes such as dopamine biosynthetic and metabolic processes, and in the cellular components axons and neuron projection . Interpretation These analyses provide important insights into the anatomical, developmental, and cellular expression patterns of genes associated with dystonia, potentially guiding the development of disease‐relevant models and improving the targeting of future therapeutic interventions.
Year:
2026
Year:
2026
Background and Hypothesis SETD1A, a histone methyltransferase, is implicated in schizophrenia through rare loss-of-function mutations. While SETD1A regulates gene expression via histone H3K4 methylation, its influence on broader epigenetic dysregulation remains incompletely understood. We explored the hypothesis that SETD1A haploinsufficiency contributes to neurodevelopmental disruptions associated with schizophrenia risk via alterations in DNA methylation. Study Design We profiled DNA methylation in the frontal cortex of Setd1a+/− mice across prenatal and postnatal development using Illumina Mouse Methylation arrays. Differentially methylated positions and regions were identified, and their functional relevance was examined through gene and biological annotation. We integrated these findings with transcriptomic and proteomics datasets, and assessed mitochondrial complex I activity to explore potential downstream functional effects. Study Results Setd1a haploinsufficiency resulted in widespread hypomethylation of genes related to ribosomal function and RNA processing that persisted across all developmental stages. Setd1a-targeted promoter regions and noncoding small nucleolar RNAs were also enriched for differentially methylated sites. Despite the downregulation of mitochondrial gene expression, the same genes were not differentially methylated, and complex I activity in Setd1a+/− mice did not differ significantly from controls. Genes overlapping hypomethylated regions were enriched for common genetic associations with schizophrenia. Conclusions Our findings suggest that SETD1A haploinsufficiency disrupts the epigenetic regulation of ribosomal pathways. These results provide insight into an alternative mechanism through which genetic variation in SETD1A influences developmental and synaptic plasticity, contributing to schizophrenia pathophysiology.
Year:
2026
Background Synaptic function is increasingly recognized as a core property of genes implicated in psychiatric disorders. Defining the specific synaptic molecular systems underlying genetic risk is critical step toward therapeutic advances. Synaptic processes rely on rapid protein production driven by local translation of mRNA in context-specific synapses. Synaptic mRNA metabolism, transport and local translation is regulated by RNA-binding proteins (RBPs). Here, we hypothesized that genetic risk converges on localised transcripts with synaptic function and aimed to identify RBP regulatory systems that capture this shared schizophrenia genetic risk. Methods We use recent human and mouse bulk and single-synapse transcriptomic and proteomic datasets to test for enrichment of schizophrenia genetic risk among mRNAs stratified by localization and synaptic function employing gene set association (MAGMA) and heritability enrichment (S-LDSC) analyses. Prioritized transcripts were further analyzed for RBP control through motif enrichment analysis (Transite) of the 3'UTRs of these transcripts. Candidate RBPs were then evaluated based on the strength of genetic association among their predicted binding targets. Results We demonstrate that genes encoding localised mRNAs with synaptic function show significantly greater genetic association than other synaptic genes. We identified a subset of RBPs, RBFOX1/2/3, CELF4, HNRNPR, and nELAVL, whose motifs are enriched in localised synaptic mRNAs and whose targets are enriched for schizophrenia risk variants. These RBPs are prioritized as candidate regulatory systems through which genetic risk may converge on the transport, splicing and translation of localised transcripts with synaptic function. Conclusions Our results highlight potential regulatory systems through which genetic variation influences synaptic mechanisms and provide a scalable framework for refining the link between genetic association and post-transcriptional regulation in neuropsychiatric disorders.
Year:
2026
Year:
2025
Objective Dystonia is one of the most common forms of movement disorder with >50 genes identified as causative. However, an understanding of which developmental stages, brain regions and cell types are most relevant is crucial for developing relevant disease models and therapeutics. One approach is to examine the timing and anatomical expression of dystonia-causing genes, on the assumption that deleterious variants have a greater impact where higher levels of expression are observed. Methods We investigated the expression patterns of 44 dystonia-causing genes across two bulk- and two single-nuclei RNA-sequencing datasets, derived from prenatal and postnatal human brain tissue. Results Dystonia genes were most strongly enriched in those with higher expression in the striatum, cerebral cortex, hippocampus, amygdala and substantia nigra, and for higher postnatal expression. Individual genes exhibiting differences in expression across adult brain regions include SQSTM1, SGCE, KMT2B, PRKRA, YY1, DNAJC12, KCNA1, CACNA1A (highest expression in cerebellum), ADCY5, GNAL, ANO3 (highest expression in striatum), RHOBTB2, FOXG1 (highest expression in cerebral cortex). Single-nuclei RNA-sequencing data analyses from human frontal cortex, striatum and cerebellum indicated that dystonia genes are predominantly expressed in neurons (both glutamatergic and GABAergic), rather than glia. Gene Ontology analysis showed prominent enrichment in biological processes such as dopamine biosynthetic and metabolic processes , and in the cellular components axons, presynapse and neuron projection . Interpretation These analyses provide important insights into the anatomical, developmental and cellular expression patterns of dystonia-causing genes, potentially guiding the development of disease-relevant models and improving the timing and targeting of future therapeutic interventions.
Year:
2025
Importance Further understanding how genetic liabilities to schizophrenia (SZ) and bipolar disorder (BD) are related to cognition and educational attainment (EA) indicates important differences between these conditions that are relevant to future research and interventions. Objective To determine how fractions of genetic liability that are shared between, and differentiate, SZ and BD, are associated with cognition and EA and characterise their biology using gene-set enrichment analysis. Design, setting and participants: Fractions of liability were derived using Genomic Structural Equation Modelling (gSEM) on genome-wide association studies of SZ and BD. Polygenic risk scores (PRS) representing each fraction were tested for association with two measures of cognition - a general cognitive factor g (n=93451) and fluid intelligence (FI, n=160465) and a measure of EA (n=354609) in the UK Biobank, excluding individuals with SZ, BD or a psychotic disorder. MAGMA and partitioned LDSC were used to examine the shared and differentiating fractions for enrichment in genes with high expression specificity for cell types, functional categories and developmental stages. Main outcomes and measures: PRS representing the shared and differentiating fractions were tested for association with FI, g and EA. Mean -log10 p-value across both MAGMA and partitioned LDSC results was used as a metric of enrichment. Results The shared fraction was associated with poorer cognition (FI beta -0.079 p=5.57e-85; g beta -0.079, p =7.51e-51) but higher EA (beta 0.016, p=5.08e-07). The SZ differentiating fraction (SZ diff ) was associated with poorer cognition (FI beta -0.027, p=6.34e-24; g beta -0.009, p=3.74e-3) and lower EA (EA beta -0.049, p=1.84e-58). The BD differentiating fraction (BD diff ) was associated with better cognition and higher EA, the effects being of the same magnitude as SZ diff but of opposite sign. Adjusting for cognitive function, the effects of SZ diff PRS on EA were attenuated but remained significantly (adjusted for FI, beta -0.025, p = 1.28e-6; adjusted for g, beta - 0.032, p = 8.87e-6). The differentiating fraction was enriched for genes specifically expressed in young adulthood (20-30 years) and mid adulthood (30-60 years), but not in earlier developmental stages. It was also enriched in murine pyramidal CA1 cells and striatal medium spiny neurones. Conclusions and relevance: Our findings partly explain the greater cognitive impairments and stronger negative genetic correlation with intelligence in SZ compared to BD. This may reflect neurodevelopmental processes indexed by cognitive function that are more prominent in SZ than BD, although the relatively modest effect of SZ diff on cognition is consistent with studies suggesting that inherited genetic variation is not the major determinant of cognitive impairment in SZ. Despite negative effects on cognition, the shared fraction is weakly associated with better EA, suggesting that this is the result of influences on noncognitive traits. In contrast, the SZ diff fraction is enriched for alleles that confer risk to poorer EA through both cognitive and non-cognitive mechanisms, which has implications for interventions. The differentiating fraction was enriched for genes with relatively high expression specificity in early and mid-adulthood, corresponding to the typical age at onset of psychotic symptoms, a clinical feature that has previously been associated with this fraction of liability.
Year:
2025
Year:
2024
Genomic studies focusing on the contribution of common and rare genetic variants of schizophrenia and bipolar disorder support the view that substantial risk is conferred through molecular pathways involved in synaptic plasticity in the neurons of cortical and subcortical brain regions, including the hippocampus. Synaptic long-term potentiation (LTP) is central to associative learning and memory and depends on a pattern of gene expression in response to neuronal stimulation. Genes related to the induction of LTP have been associated with psychiatric genetic risk, but the specific cell types and timepoints responsible for the association are unknown. Using published genomic and transcriptomic datasets, we studied the relationship between temporally defined gene expression in hippocampal pyramidal neurons following LTP and enrichment for common genetic risk for schizophrenia and bipolar disorder, and for copy number variants (CNVs) and de novo coding variants associated with schizophrenia. We observed that upregulated genes in hippocampal pyramidal neurons at 60 and 120 min following LTP induction were enriched for common variant association with schizophrenia and bipolar disorder subtype I. At 60 min, LTP-induced genes were enriched in duplications from patients with schizophrenia, but this association was not specific to pyramidal neurons, perhaps reflecting the combined effects of CNVs in excitatory and inhibitory neuron subtypes. Gene expression following LTP was not related to enrichment for de novo coding variants from schizophrenia cases. Our findings refine our understanding of the role LTP-related gene sets play in conferring risk to conditions causing psychosis and provide a focus for future studies looking to dissect the molecular mechanisms associated with this risk.
Year:
2024
Loss-of-function mutations in genes encoding lysine methyltransferases (KMTs) and demethylases (KDMs) responsible for regulating the trimethylation of histone 3 on lysine 4 (H3K4me3) are associated with neurodevelopmental conditions, including autism spectrum disorder and intellectual disability. To study the specific role of H3K4me3 demethylation, we investigated neurodevelopmental phenotypes in mice without KDM5B demethylase activity. These mice exhibited autism-like behaviours and increased brain size. H3K4me3 levels and the expression of neurodevelopmental genes were increased in the developing Kdm5b mutant neocortex. These included elevated expression of Grin2d . The Grin2d gene product NMDAR2D was increased in synaptosomes isolated from the Kdm5b -deficient neocortex and treating mice with the NMDAR antagonist memantine rescued deficits in ultrasonic vocalisations and reduced repetitive digging behaviours. These findings suggest that increased H3K4me3 levels and associated Grin2d gene upregulation disrupt brain development and function, leading to socio-communication deficits and repetitive behaviours, and identify a potential therapeutic target for neurodevelopmental disorders associated with KDM5B deficiency. Teaser Inhibitors targeting NMDA receptors may represent viable therapies for KDM5B neurodevelopmental disorders
Year:
2024
Year:
2023
Year:
2022
Collaborators (16)
Nicholas Bray
Professor
Cardiff University
Cathy Fernandes
Professor
King’s College London
Kathryn J Peall
Cardiff University
Karl Peter Giese
Professor of Neurbiology of Mental Health
King’s College London
diana Cash
King’s College London
Eilis Hannon
Associate Professor
University of Exeter Medical School
Michael O'Donovan
Professor of Psychiatric Genetics
Cardiff University
James Walters
Director and Clinical Professor
Cardiff University
Peter Holmans
Professor of Biostatistics and Genetic Epidemiology
Cardiff University
Anthony Isles
Professor
Cardiff University
Jonathan Mill
Professor
University of Exeter
Darren Cameron
Cardiff University
M. Albert Basson
Professor of Neuroscience and Epigenetics
University of Exeter
Jacob Ellegood
Research Associate
Hospital for Sick Children
Laura Andreae
King’s College London
Akshay Bhinge
Senior Lecturer
University of Exeter Medical School
Make your next move.
Prepare your application
Review drafts before you send them.